Amicus Therapeutics(US:FOLD) Newsfilter·2025-02-19 12:00Core Insights - Amicus Therapeutics reported total revenue of $528.3 million for the year 2024, marking a 33% increase year-over-year [1][4][3] - The company projects revenue growth for 2025 to be between 17% and 24% at constant exchange rates (CER) [1][4][7] - Amicus anticipates achieving positive GAAP net income during the second half of 2025 [1][7][12] Financial Performance - Total revenues for 2024 were $528.3 million, with a fourth-quarter revenue of $149.7 million, reflecting a 30% increase year-over-year [4][5] - Galafold® net product sales for 2024 were $458.1 million, an 18% increase year-over-year, while Pombiliti® + Opfolda® sales reached $70.2 million, a significant increase of 507% [5][6][12] - The company reported a GAAP net loss of $56.1 million for 2024, an improvement from a loss of $151.6 million in 2023 [12][24] Product Insights - Galafold is indicated for treating Fabry disease and is approved in over 40 countries, with approximately 2,730 patients using the drug by the end of 2024 [12][13] - Pombiliti + Opfolda received regulatory approval in multiple countries, including Australia, and is expected to see first commercial patients treated in early 2025 [5][12][16] Future Guidance - For 2025, Amicus expects Galafold revenue growth of 10% to 15% and Pombiliti + Opfolda growth of 65% to 85% at CER [7][12] - The company aims to surpass $1 billion in total sales by 2028, driven by its current product portfolio [6][12] Operational Highlights - Total GAAP operating expenses for 2024 were $450.5 million, a slight increase from $439.2 million in 2023 [12][24] - Cash, cash equivalents, and marketable securities totaled $249.9 million at the end of 2024, showing stability compared to previous quarters [12][24]